Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
A combination of OCT metrics can detect glaucoma progression sooner than a VF benchmark criterion
Author Affiliations & Notes
  • Emmanouil (Manos) Tsamis
    Ophthalmology, Columbia University, New York, New York, United States
  • Yujia Wang
    Ophthalmology, Columbia University, New York, New York, United States
  • Ari Leshno
    Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel
  • Carlos Gustavo De Moraes
    Ophthalmology, Columbia University, New York, New York, United States
  • Aakriti Garg Shukla
    Ophthalmology, Columbia University, New York, New York, United States
  • George A Cioffi
    Ophthalmology, Columbia University, New York, New York, United States
  • Jeffrey M Liebmann
    Ophthalmology, Columbia University, New York, New York, United States
  • Donald C Hood
    Ophthalmology, Columbia University, New York, New York, United States
    Psychology, Columbia University, New York, New York, United States
  • Footnotes
    Commercial Relationships   Emmanouil (Manos) Tsamis Envision Health Technologies Inc., Code C (Consultant/Contractor), Topcon Inc., Code F (Financial Support); Yujia Wang None; Ari Leshno None; Carlos Moraes Carl Zeiss, Novartis, Perfuse Therapeutics, Thea Pharma, Galimedix, Code C (Consultant/Contractor), Ora Clinical, Code E (Employment), Topcon, Carl Zeiss, RPB, Code R (Recipient); Aakriti Garg Shukla Alcon Inc., Allergan Inc, Thea Inc., Code C (Consultant/Contractor), Thea Inc., Code R (Recipient); George Cioffi None; Jeffrey Liebmann AdvanceSight, Alcon Inc., Allergan Inc., Carl Zeiss Meditech, Genentech Inc., Johnson and Johnson Inc., ONL Therapeutics Inc., Thea Inc., Code C (Consultant/Contractor); Donald Hood Novartis, Heidelberg Eng., Topcon Inc., Code F (Financial Support), Heidelberg Eng., Topcon Inc., Code R (Recipient)
  • Footnotes
    Support  NIH Grant K99-EY032182, Unrestricted Grant by Research to Prevent Blindness, Columbia University Clinical and Translational Science Award NIH UL1TR001873
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2537. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emmanouil (Manos) Tsamis, Yujia Wang, Ari Leshno, Carlos Gustavo De Moraes, Aakriti Garg Shukla, George A Cioffi, Jeffrey M Liebmann, Donald C Hood; A combination of OCT metrics can detect glaucoma progression sooner than a VF benchmark criterion. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2537.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the performance of optical coherence tomography (OCT) and visual field (VF) summary metrics in detecting progression of early glaucomatous damage.

Methods : OCT scans and 24-2 and 10-2 VFs were obtained from 107 eyes [37 healthy controls (HC), 70 patients with early glaucoma, at least 4 tests (mean: 10.3±1.5 tests) and at least 2 years between baseline (first) and the last follow-up test (range: 2.0–6.8yrs). Based on confirmation of structural and functional evidence of progression, two graders independently judged 21 of the 70 patient eyes as ‘Progressors’ (P). In addition, 42 eyes were judged ‘stable’ (S), based upon a lack of evidence of change on OCT and VF. Metrics of the circumpapillary retinal nerve fiber layer (cpRNFL) and the macular ganglion cell layer (GCL) thickness were extracted from the OCT scans. From the 24-2 and 10-2 VFs, we recorded the total deviation values from each test location and the mean deviation (MD) global index for both patterns. A benchmark criterion (BC) of progression of 7dB loss in at least 5 locations was used as a ‘benchmark’. Linear regression over time was performed for all metrics. A negative slope less than a criterion value based on the HC eyes and a 95% specificity was deemed progressing. A Kaplan-Meier method identified the time to detect progression.

Results : The 24-2 and 10-2 BC labelled 6 S eyes as ‘progressing’, for a specificity of 86% (Table 1). The sensitivity was remarkably low, 38% (24-2) and 52% (10-2). Only one metric, the 24-2 MD Superior, had similar specificity (88%) and sensitivity (52%). All other OCT and VF metrics had worse specificity. Notably, all OCT metrics had the same or better sensitivity than the BC, ranging from 52% to 86%. Composite metrics of Structure-Structure (S-S) and Structure-Function (S-F) showed higher specificity and sensitivity than the BC. The best performing metric, an S-S metric (Table, red), which evaluates cpRNFL and GCL topographic agreement, had a specificity of 93% and a sensitivity of 86%, detecting nearly half of P eyes within 2 years. (Fig.1, green)

Conclusions : A strict benchmark criterion based upon pointwise VF loss was not as highly specific as anticipated. OCT and VF metrics, in isolation, had similar or worse performance. A S-S metric achieved the highest specificity and sensitivity and detected progression in half the eyes within 2 years.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×